Disitamab vedotin (RC48-ADC) combined with immunotherapy as neoadjuvant therapy for localized muscle-invasive bladder cancer: a multicenter real-world study.

ABSTRACT: Neoadjuvant cisplatin-based combination chemotherapy or perioperative durvalumab with neoadjuvant gemcitabine-cisplatin has been the primary treatment for localized muscle-invasive bladder cancer (MIBC). Nevertheless, many patients are either cisplatin-ineligible or relapse after standard therapy. This multicenter, retrospective real-world study evaluated disitamab vedotin (RC48) plus PD-1 inhibitors as neoadjuvant therapy for localized MIBC. Twenty-five patients (cT2-4aN0-2M0) received at least four cycles of RC48 (2.0 mg/kg, Q2W or Q3W) with toripalimab, tislelizumab, or pembrolizumab, followed by radical cystectomy. The pathological complete response rate was 48%, and the pathological downstaging rate was 88%. After a median follow-up of 17.0 months, 12-month disease-free and overall su

SUBMITTER: Guo X 

PROVIDER: S-EPMC12780152 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature